Encodes An Animal Polypeptide Patents (Class 536/23.5)
-
Publication number: 20130296247Abstract: The present invention relates to a peptide and analogs thereof that selectively inhibit the Nav1.7 sodium channel. The present invention also relates to pharmaceutical compositions useful for treating or preventing a disorder responsive to the blockade of sodium ion channels, especially Nav1.7 sodium ion channels. The present invention further provides methods of treating a disorder responsive to the blockade of sodium channels, and particularly Nav1.7 sodium channels, in a mammal suffering from excess activity of said channels, compositions and methods for providing analgesia by administering a peptide of the invention.Type: ApplicationFiled: July 7, 2011Publication date: November 7, 2013Applicant: PURDUE PHARMA L.P.Inventors: Jae Hyun Park, Donald J. Kyle
-
Publication number: 20130295666Abstract: The present invention pertains to crystals of glucokinase regulatory protein (GKRP) and of GKRP variants, to the molecular biology of certain GKRP variants, to processes for the crystallization of GKRP and GKRP variants, to such crystals and corresponding structural information obtained by X-ray crystallography. Such crystals and crystallographic data can be used for the identification of compounds that bind to GKRP, especially of compounds that inhibit GKRP or interfere with the interaction of GKRP with its natural interacting partner Glucokinase (GK).Type: ApplicationFiled: December 17, 2012Publication date: November 7, 2013Applicant: Boehringer Ingelheim International GmbHInventors: Gisela SCHNAPP, Adina Berg, Stefan Kauschke, Martin Lenter, Alexander Pautsch, Wolfgang Rist
-
Publication number: 20130296406Abstract: Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated molecule comprising a nucleic acid sequence that codes for light-activated molecule. The light-activated molecule includes a modification to a location near the all-trans retinal Schiff base, e.g., to extends the duration time of the open state. Other aspects and embodiments are directed to systems, methods, kits, compositions of matter and molecules for ion channels or pumps or for controlling currents in a cell (e.g., in vivo or in vitro environments).Type: ApplicationFiled: April 1, 2013Publication date: November 7, 2013Inventors: Karl Deisseroth, Ofer Yizhar, Lisa Gunaydin, Peter Hegemann, Andre Berndt
-
Publication number: 20130298263Abstract: The present invention provides a nucleic acid construct for expressing an oxidative stress indicator comprising: a nucleic acid sequence encoding an Nrf2 protein-derived partial protein that comprises at least an Neh2 domain sequence and substantially lacks or is functionally deficient in an Neh1 domain sequence or an Neh1-Neh3 domain sequence; a stress-inducible promoter sequence positioned upstream of the nucleic acid sequence encoding an Nrf2 protein-derived partial protein; and a nucleic acid sequence encoding a protein capable of generating a detectable signal, the nucleic acid sequence being positioned downstream of the nucleic acid sequence encoding an Nrf2 protein-derived partial protein. The present invention also provides a method for measuring oxidative stress and a method for screening for an anti-oxidative stress agent, using the nucleic acid construct.Type: ApplicationFiled: January 20, 2012Publication date: November 7, 2013Inventors: Takao Iwawaki, Daisuke Oikawa
-
Publication number: 20130296221Abstract: Improved N-terminal capping modules for designed ankyrin repeat proteins (DARPins) conferring improved thermal stability to the DARPins are described, as well as nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.Type: ApplicationFiled: November 25, 2011Publication date: November 7, 2013Applicant: Molecular Partners AGInventor: Hans Kaspar Binz
-
Publication number: 20130296252Abstract: Provided are MUC18 targeting peptides which may be used, e.g., to therapeutically target B-1 lymphocytes to reduce the influence of these cells on the metastatic potential of melanoma cells and/or to target cancerous cells, including certain melanoma and leukemia cells. MUC18 targeting peptides may be comprised in fusion constructs, imaging constructs, and/or therapeutic constructs such as fusion constructs which may be used for diagnosing or treating a cancer.Type: ApplicationFiled: April 29, 2013Publication date: November 7, 2013Inventors: Fernanda STAQUICINI, Renata PASQUALINI, Wadih ARAP
-
Publication number: 20130296244Abstract: The present invention is in the field of hemophilia therapy. It relates to a new variant of antihemophilic factor VIII having increased specific activity in comparison to known factor VIII products.Type: ApplicationFiled: November 4, 2011Publication date: November 7, 2013Applicants: Baxter Heathcare SA, Baxter International Inc.Inventors: Chee K. Lai, Roddy Kevin Stafford
-
Publication number: 20130296241Abstract: This document provides aquaretic and natriuretic polypeptides. For example, this document provides polypeptides having aquaretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have aquaretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing aquaretic and/or natriuretic activities within a mammal.Type: ApplicationFiled: July 16, 2013Publication date: November 7, 2013Inventors: Horng H. Chen, John C. Burnett, Jr.
-
Publication number: 20130295593Abstract: Vitamin D binding proteins (DBP), in particular truncated DBP and mutated, truncated DBP, as well as fusion proteins thereof, nucleic acid molecules encoding same, vectors, host cells, and methods, kits and solid supports for determining the total amount of 25-hydroxy vitamin D2 and 25-hydroxy vitamin D3 in a test sample.Type: ApplicationFiled: December 23, 2012Publication date: November 7, 2013Inventors: Christian Beckert, Susan E. Brophy, Jonathan Grote, Dagang Huang, Jan Schultess, Bailin Tu
-
Patent number: 8575322Abstract: The present disclosure relates to a field of recombinant DNA therapeutics. It involves the bio-informatics design, synthesis of artificial gene for human insulin precursor including leader peptide coding sequence, cloning in an expression vector and expression in an organism, preferably Pichia pastoris. The present disclosure also relates to methods of downstream processing for obtaining protein precursor molecules and subsequent conversion of precursor molecules to functional proteins.Type: GrantFiled: March 12, 2010Date of Patent: November 5, 2013Assignee: Bigtec Private LimitedInventors: Mulakkapurath Narayanan Manoj, Venkata Ramachandra Rao Vasamsetty, Madhuri Baliga, Kirubakaran Naveen Kumar, Chandrasekhar Bhaskaran Nair, Pillarisetti Venkata Subbarao
-
Publication number: 20130289252Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or O2 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.Type: ApplicationFiled: February 20, 2013Publication date: October 31, 2013Inventors: Stephen P. L. CARY, Elizabeth M. BOON, Jonathan A. WINGER, Michael A. MARLETTA
-
Publication number: 20130287806Abstract: This invention discloses the use of Heminth Defense Molecules in methods and compositions for modulating immune responses including treating or preventing undesirable or deleterious immune responses.Type: ApplicationFiled: November 1, 2011Publication date: October 31, 2013Applicant: UNIVERSITY OF TECHNOLOGY, SYDNEYInventors: Sheila Donnelly, Mark William Robinson, John Pius Dalton, Joyce To
-
Publication number: 20130287681Abstract: Methods and composition for cell-based therapy as well as somatostatin receptor-based therapy are described. For example, in certain aspects methods for administering an anti-tumor therapy using a signaling defective somatostatin receptor mutant are described. Furthermore, the invention provides compositions and methods involve a somatostatin constitutively active somatostatin receptor mutant.Type: ApplicationFiled: September 8, 2011Publication date: October 31, 2013Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventor: Vikas Kundra
-
Publication number: 20130288906Abstract: The invention relates to novel variants that associate with Alzheimer's disease AD and their use in kits as a means for diagnosing AD; and also their use in nucleic acid molecules or cells/cell lines for identifying novel therapeutic, label of identification means.Type: ApplicationFiled: May 3, 2013Publication date: October 31, 2013Inventors: Julie Williams, Michael John Owen
-
Publication number: 20130288970Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: ApplicationFiled: February 20, 2013Publication date: October 31, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: The Regents Of The University Of California
-
Publication number: 20130288364Abstract: The invention provides modified DNA-binding kinetochore polypeptides, wherein the modified DNA binding kinetochore polypeptides comprise a heterologous DNA binding domain. The invention further provides engineered kinetochores containing the modified kinetochore polypeptides. Further provided are artificial chromosomes containing an engineered kinetochore. Cells containing an artificial chromosome containing an engineered kinetochore are also provided. Methods for producing and methods of using the engineered kinetochore, artificial chromosome, and cells are also provided.Type: ApplicationFiled: October 28, 2011Publication date: October 31, 2013Applicant: Whitehead Institute for Biomedical ResearchInventors: Iain Cheeseman, Karen Gascoigne
-
Publication number: 20130289261Abstract: The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC).Type: ApplicationFiled: July 11, 2013Publication date: October 31, 2013Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Olivera J. Finn, Nehad M. Alajez, Jan Schmielau, Mark D. Alter
-
Publication number: 20130288948Abstract: A motif is searched which can inhibit the proteolysis of a protein that has been administered to a cell or an individual. Thus, disclosed is a method for designing/producing a protein having resistance to proteolysis. Specifically disclosed is a motif capable of inhibiting proteolysis, which comprises an amino acid region lying between the 396th position and the 410th position from the C-terminal of DP-1.Type: ApplicationFiled: November 20, 2009Publication date: October 31, 2013Applicant: NIHON UNIVERSITYInventors: Shigemasa Hanazawa, Yoshikazu Masuhiro
-
Publication number: 20130288363Abstract: It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.Type: ApplicationFiled: May 23, 2013Publication date: October 31, 2013Inventors: Yasuharu NISHIMURA, Yoshiaki IKUTA, Shuichi NAKATSURU
-
Patent number: 8568709Abstract: The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.Type: GrantFiled: March 20, 2009Date of Patent: October 29, 2013Assignee: University Health NetworkInventors: Jeffrey A. Medin, Sean Devine
-
Patent number: 8569471Abstract: The invention relates to methods and compositions for selectively directing stem cells to a target tissue within a subject using a system that employs one or more vectors that contain a gene switch/biosensor, a tissue-specific promoter, a gene encoding a stem cell-attracting chemokine, and a gene amplification system. In one embodiment, a stem cell-attracting chemokine is expressed in damaged tissue using a stimulus-responsive vector system. The stimulus can be a physiological stimulus associated with cell injury, such as hypoxia or elevated glucose levels, for example. Expression of the chemokine increases the trafficking of stem cells to the damaged tissue.Type: GrantFiled: November 18, 2011Date of Patent: October 29, 2013Assignee: University of South FloridaInventors: M. Ian Phillips, Yao Liang Tang
-
Patent number: 8568707Abstract: Provided are diagnostic and pharmaceutical compositions containing a microorganism or a cell containing a DNA molecule encoding a detectable protein or a protein that a detectable signal, such as a luminescent or fluorescent protein. Methods of tumor targeting and tumor imaging using the microorganisms and cells are provided. Also provided are therapeutic methods in which the microorganisms and cells, which can encoded a therapeutic protein, such as a cytotoxic or cytostatic protein, are administered.Type: GrantFiled: June 10, 2004Date of Patent: October 29, 2013Assignee: Genelux CorporationInventors: Aladar A. Szalay, Yong A. Yu, Tatyana Timiryasova, Shahrokh Shabahang
-
Publication number: 20130280166Abstract: The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.Type: ApplicationFiled: April 16, 2013Publication date: October 24, 2013Inventors: Özlem TÜRECI, Ugur SAHIN, Gerd HELFTENBEIN, Volker SCHLÜTER
-
Publication number: 20130281356Abstract: The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein.Type: ApplicationFiled: March 14, 2013Publication date: October 24, 2013Inventors: Michael W. Tusche, Tak W. Mak, Pamela S. Ohashi, Philipp Lang, Karl Lang, Dirk Brenner, Gloria Lin
-
Publication number: 20130281357Abstract: Anti-angiogenic agents or polypeptides comprising an amino acid segment substantially similar to domain one of CD2 wherein the polypeptide has a ?-sheet formed by two segments. Methods of using such agents and polypeptide are also included.Type: ApplicationFiled: July 13, 2011Publication date: October 24, 2013Applicant: Georgia State University Research FoundationInventors: Zhi-Ren Liu, Jenny J. Yang, Yin Lu
-
Publication number: 20130280290Abstract: The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a vaccine formulation as a purified protein and/or naked DNA, to induce an immune response in aquatic organisms against different ectoparasite species, including the known as sea lice, and pathogens associated with these infestations. The vaccine preparations, administered by oral route, immersion bath or injection, demonstrated its efficacy by producing IgM humoral immune response and reducing the number of parasites per fish in the vaccinated fishes.Type: ApplicationFiled: April 9, 2013Publication date: October 24, 2013Inventors: Yamila Carpio Gonzalez, Mario Pablo Estrada Garcia
-
Publication number: 20130280222Abstract: Compositions and methods are provided for integrating one or more genes of interest into cellular DNA without substantially disrupting the expression of the gene at the locus of integration, i.e., the target locus. These compositions and methods are useful in any in vitro or in vivo application in which it is desirable to express a gene of interest in the same spatially and temporally restricted pattern as that of a gene at a target locus while maintaining the expression of the gene at the target locus, for example, to treat disease, in the production of genetically modified organisms in agriculture, in the large scale production of proteins by cells for therapeutic, diagnostic, or research purposes, in the induction of iPS cells for therapeutic, diagnostic, or research purposes, in biological research, etc. Reagents, devices and kits thereof that find use in practicing the subject methods are also provided.Type: ApplicationFiled: March 15, 2013Publication date: October 24, 2013Inventors: Mark A. Kay, Matthew Porteus, Jenny Barker, Josh Checketts, Richard Voit, Adi Barzel
-
Patent number: 8563703Abstract: The present invention provides nucleic acid molecules encoding novel red fluorescent proteins from Entacmaea quadricolor and mutants thereof. Also of interest are proteins that are substantially similar to the novel red fluorescent proteins. In addition, host cells, stable cell lines and transgenic organisms comprising the nucleic acid molecules encoding the novel red fluorescent proteins are provided. The subject proteins and nucleic acid compositions find use in a variety of different applications and methods, particularly for labeling of biomolecules, cells, or cell organelles. Finally, kits for use in such methods and applications are provided.Type: GrantFiled: February 2, 2012Date of Patent: October 22, 2013Assignee: Evrogen IP Joint Stock CompanyInventors: Sergey A. Lukyanov, Dmitry M. Chudakov
-
Patent number: 8563705Abstract: This document relates to methods and materials for using nucleic acid and amino acid sequence variants of ribonucleic acid binding motif protein 20 (RBM20). For example, methods and materials for using nucleic acid sequence variants and/or their corresponding amino acid variants of RBM20 that are associated with dilated cardiomyopathy to identify mammals (e.g., humans) at risk of having dilated cardiomyopathy that is likely to progress to heart failure are provided.Type: GrantFiled: May 11, 2011Date of Patent: October 22, 2013Assignee: Mayo Foundation for Medical Education and ResearchInventor: Timothy M. Olson
-
Patent number: 8562970Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.Type: GrantFiled: October 6, 2004Date of Patent: October 22, 2013Assignee: Sanofi Pasteur LimitedInventors: Mark Parrington, Linong Zhang, Benjamin Rovinski, Linda Gritz, Patricia Greenhaigh
-
Publication number: 20130273647Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.Type: ApplicationFiled: September 19, 2011Publication date: October 17, 2013Applicants: BIONTECH AG, TRON- Translationale Onkologie an der Universi- ttttatsmedzin der Johannes Gutenberg- UNiversitat, Universitatsmedizin der Johannes Gutterberg- Universital MAinzInventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
-
Publication number: 20130274203Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.Type: ApplicationFiled: September 14, 2011Publication date: October 17, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventor: Dhanalakshmi Chinnasamy
-
Publication number: 20130273596Abstract: DNA enhancer sequences are provided for use in constructs to identify early stage embryonic cells. The enhancer sequences can be used in parallel with short-hairpin RNA in a vector construct for endogenously regulated gene knockdowns. The disclosed enhancer sequences can be used to isolate a selected population of early stage embryonic cells.Type: ApplicationFiled: April 5, 2013Publication date: October 17, 2013Inventors: Tatjana Sauka-Spengler, Sonja J. McKeown, Paola Betancur, Marianne Bronner
-
Publication number: 20130276157Abstract: Novel mutations in cytochrome P450C17 (CYP17) and cytochrome b5 (CYB5) affecting 16-androstene steroid synthesis are disclosed. The novel mutations result in alterations in production of critical intermediaries in the synthesis of 16-androstene steroids. Altering the activity of these enzymes may be useful in enhancing reducing androstenone synthesis and reducing boar taint. The identification of these novel mutations also allows for the development of transgenic pigs bearing mutations in these enzymes or for genetic screening to identify pigs on the basis of their CYP17 and/or CYB5 genotype. Pigs having these mutations may be selected and bred to produce pigs that have a lower incidence of boar taint.Type: ApplicationFiled: March 8, 2013Publication date: October 17, 2013Inventor: E. James Squires
-
Publication number: 20130276155Abstract: A family of insecticidal polypeptides expressed in the venom gland of spiders of the genera Atrax and Hadronyche have been described. Also included are polynucleotides and expression vectors encoding the polypeptides and insect viruses and cells expressing the polypeptides. Transgenic plants and insects expressing the insecticidal polypeptides are also described. The insecticidal polypeptides may be employed in methods and compositions for treating insects, insect larvae, and plants.Type: ApplicationFiled: September 28, 2012Publication date: October 17, 2013Applicants: University of Technology, Sydney, University of ConnecticutInventors: University of Connecticut, University of Technology, Sydney
-
Publication number: 20130273112Abstract: Provided herein is consensus amino acid sequences of P. falciparum (P.f.) proteins and their encoding sequences, as well as expression constructs expressing the sequences. Also provided herein are methods for generating an immune response against P. falciparum using the expression constructs provided herein.Type: ApplicationFiled: September 27, 2011Publication date: October 17, 2013Inventors: David B. Weiner, Bernadette Ferraro, Jian Yan, Niranjan Y. Sardesai
-
Publication number: 20130273111Abstract: The polynucleotide encoding the antigen Wb123 from the filarial nematode Wuchereria bancrofti, the major causative organism of lymphatic filariasis is provided, along with the polypeptide encoded by the polynucleotide. Methods for making the WM23 antigen, recombinant vectors encoding the Wb123 polynucleotide, and methods of detection of the Wb123 antigen through luciferase immunprecipitation, ELISA and other detection systems are also provided.Type: ApplicationFiled: October 31, 2011Publication date: October 17, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Thomas B. Nutman, Doran Fink, Joseph Kubofcik, Peter D. Burbelo
-
Publication number: 20130274172Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.Type: ApplicationFiled: March 26, 2013Publication date: October 17, 2013Inventors: William D. Carlson, Peter C. Keck
-
Patent number: 8556882Abstract: The invention provides an isolated or purified nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12. The invention also provides a nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12, wherein the NFAT promoter is located 3? of the nucleotide sequence encoding IL-12. Also provided are related recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. The invention further provides the use of the inventive nucleic acids or related materials in the treatment or prevention of cancer or an infectious disease in a mammal and in the induction of IL-12 expression in a mammal.Type: GrantFiled: April 22, 2010Date of Patent: October 15, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard A. Morgan, Steven A. Rosenberg, Ling Zhang, Nicholas P. Restifo
-
Publication number: 20130267682Abstract: To provide a new natural fiber material with excellent physical properties. Any one of the following nucleic acids (a) to (d): (a) a nucleic acid having a base sequence of SEQ ID NO: 1 or 19; (b) a nucleic acid encoding a protein having an amino acid sequence of SEQ ID NO: 2 or 20; (c) a nucleic acid encoding a dragline protein and having a sequence identity of 90% or more with the nucleic acid (a); (d) a nucleic acid which encodes a dragline protein and hybridizes with a complementary chain of the nucleic acid (a) under stringent conditions.Type: ApplicationFiled: June 18, 2013Publication date: October 10, 2013Inventors: Tianfu ZHAO, Yujun WANG, Masao NAKAGAKI
-
Publication number: 20130266958Abstract: The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to any MHC class II molecule of an HLA-DRB1* 0101 molecule, an HLA-DRB1* 0401 molecule, an HLA-DRB1* 0403 molecule, an HLA-DRB1* 0406 molecule, an HLA-DRB1* 0803 molecule, an HLA-DRB1* 0901 molecule, an HLA-DRB1* 1101 molecule, an HLA-DRB3* 0202 molecule, an HLA-DRB4* 0101 molecule, an HLA-DPB1* 0201 molecule or an HLA-DPB1* 0301 molecule, and the like.Type: ApplicationFiled: October 4, 2011Publication date: October 10, 2013Applicants: OTSUKA PHARMACEUTICAL CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INCInventors: Haruo Sugiyama, Shinji Sogo, Masayoshi Sato, Ryuki Kitamoto, Yoshihiro Goto
-
Publication number: 20130266597Abstract: The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.Type: ApplicationFiled: December 21, 2012Publication date: October 10, 2013Inventors: Robert E.W. Hancock, Kai Hilpert, Artem Cherkasov, Christopher Fjell
-
Publication number: 20130266936Abstract: The invention relates to the diagnosis, prognosis, monitoring, and treatment of neoplastic diseases such as tumor diseases, especially tumor diseases of the endometrium and the metastases thereof.Type: ApplicationFiled: December 20, 2012Publication date: October 10, 2013Inventors: Eric STEINER, Jan HENGSTLER, Jens Sagemüller
-
Publication number: 20130266598Abstract: The invention provides methods for identifying a HLA-B*0702-restricted cryptic epitope in an antigen, as well as methods for increasing the immunogenicity of HLA-B*0702-restricted cryptic epitopes. The HLA-B*0702-restricted cryptic epitopes and their cognate immunogenic epitopes are useful for stimulating an immune reaction against the cryptic epitopes in a subject. Accordingly, the invention further provides pharmaceutical compositions comprising a HLA-B*0702-restricted cryptic epitope or a cognate immunogenic epitope thereof, and vaccination kits comprising such epitopes. The novel materials of the invention are particularly useful for efficiently treating patients having an HLA-B*0702 phenotype.Type: ApplicationFiled: June 17, 2013Publication date: October 10, 2013Inventors: Kostantinos Kosmatopoulos, Stéphanie Graff-Dubois, Jeanne Menez-Jamet
-
Publication number: 20130267676Abstract: The present invention provides a fibronectin type III (Fn3) molecule, wherein the Fn3 contains a stabilizing mutation. The present invention also provides Fn3 polypeptide monobodies, nucleic acid molecules encoding monobodies, and variegated nucleic acid libraries encoding such monobodies. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform the methods.Type: ApplicationFiled: August 2, 2012Publication date: October 10, 2013Inventor: Shohei Koide
-
Publication number: 20130267025Abstract: A polypeptide capable of strongly inducing and activating dendritic-cell-like cells for treating or prevent cancer by immunotherapy, and DNA encoding the polypeptide. The polypeptide is a polypeptide (a) or (b) consisting of a partial region of the REIC/Dkk-3 protein.Type: ApplicationFiled: July 1, 2011Publication date: October 10, 2013Applicants: Momotaro-Gene Inc., NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITYInventors: Hiromi Kumon, Masami Watanabe, Junichiro Futami, Yasuyuki Fujii, Hideo Ueki, Kazuhiko Ochiai
-
Publication number: 20130267030Abstract: The invention provides a method of improving the efficiency of establishment of induced pluripotent stem cells by increasing, in a nuclear reprogramming step of somatic cell, the level of activated form of one or more proteins selected from the group consisting of Ras family members, PI3 kinase, RalGEF, Raf, AKT family members, Rheb, TCL1 and S6K. The invention also provides a method of producing induced pluripotent stem cells by contacting a somatic cell with a nuclear reprogramming substance and one or more of such proteins and nucleic acids that encode such proteins. The invention further provides an induced pluripotent stem cell that has an exogenous nucleic acid encoding such a protein, as well as agents for use in the aforesaid methods.Type: ApplicationFiled: December 2, 2011Publication date: October 10, 2013Applicant: KYOTO UNIVERSITYInventors: Shinya Yamanaka, Kazutoshi Takahashi, Koji Tanabe
-
Patent number: 8551945Abstract: Disclosed herein are methods and compositions for treating neuropathies by modulating endogenous NT-3 of GDNF gene expression.Type: GrantFiled: February 4, 2010Date of Patent: October 8, 2013Assignee: Sangamo BioSciences, Inc.Inventors: Carolyn Dent, Josee Laganiere, Xiangdong Meng, David Paschon, Siyuan Tan, Lei Zhang, Steve H. Zhang
-
Patent number: 8551772Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: GrantFiled: November 22, 2011Date of Patent: October 8, 2013Assignee: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, Gary Rosenberg, Christina A Scherer, Thierry Guillaudeux
-
Publication number: 20130259929Abstract: The present invention concerns the use of a phosphopeptide able to block HER3/p85 interaction for the treatment of HER2 hyper-expressing tumours, such as, for example, metastatic mammary tumour, possibly in combination with other anti-tumour agents like, for example, trastuzumabType: ApplicationFiled: September 29, 2011Publication date: October 3, 2013Inventors: Rita Falcioni, Valentina Folgiero, Selene Eleonora Di Carlo, Giulia Bon